Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Pharm Res. 2012 Nov;35(11):1855-9. doi: 10.1007/s12272-012-1101-z.

Recent updates on the development of ganetespib as a Hsp90 inhibitor.

Author information

  • 1Faculty of Convergence Science, Jungwon University, Goesan 367-805, Korea.

Abstract

Heat shock protein 90 (Hsp90) plays a critical role in the maintenance of multiple oncogenic pathways and is a required protein for folding and stability of many oncoproteins that are related to the growth, proliferation, and survival of many kinds of cancers. Ganetespib (STA-9090) is a potent, synthetic, small molecule inhibitor of Hsp90, and its binding to Hsp90 is known to result in the degradation of its client proteins and subsequent death of cancer cells. This article provides a review of ganetespib as one of the leading Hsp90 inhibitors, which is under investigation in a broad range of clinical stages for the treatment of cancer.

PMID:
23212626
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk